Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 18, 2023Frontiers in OncologyOpen Access

The expression of Ki-67 and Glypican -3 in hepatocellular carcinoma was evaluated by comparing DWI and 18F-FDG PET/CT

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXuedong WangLLLei LiLWLinjie Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2023) studied this question.

synapsesocial.com/papers/6a7164618031ec7bb1dcf211https://doi.org/10.3389/fonc.2023.1026245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hepatocellular Carcinoma2019 · 4,746 citations
  2. 2Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment2017 · 407 citations
  3. 3Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma2017 · 43 citations
  4. 4Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma2018 · 71 citations
  5. 5Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment2022 · 27 citations